Inmune Bio, Inc. — Investor Relations & Filings
Filings indexed
572
across all filing types
Latest filing
2026-06-02
Regulatory Filings
Country
US
United States of America
Listing
US
INMB
Inmune Bio, Inc. is a clinical-stage biotechnology company that develops therapies by reprogramming the patient's innate immune system to fight disease. The company's pipeline is focused on treating cancer and neurodegenerative disorders, particularly Alzheimer's disease. Its lead product candidates include XPro1595, a selective inhibitor of soluble Tumor Necrosis Factor (TNF) for treating neuroinflammation, and INKmune®, a tumor-agnostic therapy designed to prime a patient's natural killer (NK) cells to attack cancer. Inmune Bio's clinical development approach prioritizes matching a drug's mechanism of action to patient biology and using patient-centric outcome metrics.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| CURRENT REPORT | 2026-06-02 | English | |
| DEF 14A - Inmune Bio, Inc. (0001711754) (Filer) | 2026-04-23 | English | |
| 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-27 | English | |
| 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-23 | English | |
| 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-19 | English | |
| 8-K Filing | 2026-02-13 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 47938740 | CURRENT REPORT | 2026-06-02 | English | ||
| 35868237 | DEF 14A - Inmune Bio, Inc. (0001711754) (Filer) | 2026-04-23 | English | ||
| 32897132 | 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-27 | English | ||
| 32897130 | 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-23 | English | ||
| 32897131 | 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-19 | English | ||
| 31423861 | 8-K Filing | 2026-02-13 | English | ||
| 31423822 | 8-K Filing | 2026-01-27 | English | ||
|
2025
8 filings
| |||||
| 13050483 | CURRENT REPORT | 2025-12-23 | English | ||
| 13050482 | CURRENT REPORT | 2025-12-19 | English | ||
| 13050485 | PROSPECTUS SUPPLEMENT | 2025-12-19 | English | ||
| 13050484 | CURRENT REPORT | 2025-12-10 | English | ||
| 13050486 | AMENDMENT NO. 5 TO FORM 8-A12B | 2025-12-08 | English | ||
| 13050488 | CURRENT REPORT | 2025-12-08 | English | ||
| 13050487 | CURRENT REPORT | 2025-12-05 | English | ||
| 13050492 | CURRENT REPORT | 2025-12-03 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CAPRICOR THERAPEUTICS, INC.
A clinical-stage biotech developing cell and exosome-based …
|
CAPR | US | Manufacturing |
|
Cardiogeni Plc
A clinical-stage biotech developing regenerative medicines …
|
— | GB | Manufacturing |
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory and ant…
|
CRDL | CA | Manufacturing |
|
CAREGEN CO.,LTD.
Develops biomimetic peptides and growth factors for aesthet…
|
214370 | KR | Manufacturing |
|
Caribou Biosciences, Inc.
Clinical-stage biopharma developing genome-edited allogenei…
|
CRBU | US | Manufacturing |
|
Carisma Therapeutics Inc.
A clinical-stage biotech developing engineered macrophage-b…
|
CARM | US | Manufacturing |
|
Carna Biosciences, Inc.
Clinical-stage biopharma developing small molecule kinase i…
|
4572 | JP | Manufacturing |
|
CARsgen Therapeutics Holdings Limited
Clinical-stage biopharma focused on developing innovative C…
|
2171 | HK | Manufacturing |
|
Cartesian Therapeutics, Inc.
A clinical-stage company developing mRNA-engineered cell th…
|
RNAC | US | Manufacturing |
|
CASI Pharmaceuticals, Inc.
Biopharmaceutical firm developing therapeutics for organ tr…
|
CASI | US | Manufacturing |
Inmune Bio, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34518/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34518 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34518 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34518 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34518}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Inmune Bio, Inc. (id: 34518)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.